Besifloxacin Ophthalmic Suspension 0.6% Compared with Gatifloxacin Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis in Neonates

Antibiotic Resistance Among Ocular Pathogens in the United States

(2015) Penny A. Asbell et al.   JAMA Ophthalmology

Efficacy and safety of azithromycin 1.5% eye drops in paediatric population with purulent bacterial conjunctivitis

(2014) Dominique Bremond-Gignac et al.   BRITISH JOURNAL OF OPHTHALMOLOGY

Trends in ophthalmic manifestations of methicillin-resistant Staphylococcus aureus (MRSA) in a northern California pediatric population

(2013) Malena Amato et al.   JOURNAL OF AAPOS

Comparative In Vitro Susceptibility of Besifloxacin and Seven Comparators Against Ciprofloxacin- and Methicillin-Susceptible/Nonsusceptible Staphylococci

(2013) Darlene Miller et al.   JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS

Etiologic and Therapeutic Pitfalls of Newborn Conjunctivitis

(2012) Stan L. Block   PEDIATRIC ANNALS

Monitoring Antibiotic Resistance in Ocular Microorganisms: Results From the Antibiotic Resistance Monitoring in Ocular MicRorganisms (ARMOR) 2009 Surveillance Study

(2011) Wolfgang Haas et al.   AMERICAN JOURNAL OF OPHTHALMOLOGY

In vitro time-kill experiments with besifloxacin, moxifloxacin and gatifloxacin in the absence and presence of benzalkonium chloride

(2011) W. Haas et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Efficacy and Safety of Besifloxacin Ophthalmic Suspension 0.6% in Children and Adolescents with Bacterial Conjunctivitis

(2010) Timothy L. Comstock et al.   PEDIATRIC DRUGS

Besifloxacin, a Novel Fluoroquinolone, Has Broad-Spectrum In Vitro Activity against Aerobic and Anaerobic Bacteria

(2009) W. Haas et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: A multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study

(2009) Paul Karpecki et al.   CLINICAL THERAPEUTICS

Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis

(2009) Michael E. Tepedino et al.   CURRENT MEDICAL RESEARCH AND OPINION

Efficacy and Safety of Besifloxacin Ophthalmic Suspension 0.6% Compared with Moxifloxacin Ophthalmic Solution 0.5% for Treating Bacterial Conjunctivitis

(2009) Marguerite B. McDonald et al.   OPHTHALMOLOGY

Trends in Incidence of Late-Onset Methicillin-Resistant Staphylococcus aureus Infection in Neonatal Intensive Care Units

(2009) Fernanda C. Lessa et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL